Sanofi signed an exclusive collaboration to use Atomwise's AtomNet on up to five drug targets.

Drug discovery for hard-to-drug or poorly characterised targets is inefficient. AtomNet, a deep learning structure-based design platform, searches over three trillion synthesizable compounds for up to five targets. The article states $20M upfront and potential milestones above $1B plus royalties.

Atomwise is an AI drug discovery company whose AtomNet deep learning platform performs virtual screening for pharma and academic partners.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.